The top 20 global animal health companies achieved combined revenue of USD 38.6 billion in 2024, with a compound growth rate of 9% over the last decade according to HealthForAnimals. Fortune Business Insights estimates the overall animal health market at USD 70.16 billion in 2025, with projections of USD 187.79 billion in 2034 and CAGR of 11.56%. The veterinary medicines segment, within the broader frame, is estimated by Mordor Intelligence at USD 27.4 billion in 2025, with companion animals representing 51.57% of the mix and expected growth of 7.82% to 2031, versus 5.49% for livestock. The proportions of individual players reflect the duality: Zoetis, leader with more than 11% global share and approximately USD 7.35 billion in product revenue in 2025, has a mix of around 65% companion and 35% livestock.
The structure of the 2026 animal health market is clear: two segments that share the same professional figure — the veterinarian — but have different decision cycles, commercial KPIs, regulatory constraints and purchasing dynamics. For companies in the sector planning CRM, sales organization and distribution model, the temptation to treat the two markets with the same infrastructure leads to significant inefficiencies. Structural separation is the choice that established players made long ago, and that emerging players must make in the scaling phase.
Pet care: premiumization and humanization
The companion animal segment — pet care — is characterized by sustained premiumization dynamics and "humanization" of consumption: the owner of a dog or cat attributes to the animal the status of a family member and seeks for its health solutions that mirror human medicine standards. Long-acting parasiticides such as Bravecto and Simparica Trio, monoclonals for chronic pain such as Librela and Solensia, cardiology and dermatology drugs for pets, veterinary-prescribed diets, specific supplements: the assortment has exploded over the last decade, with unit margins significantly higher than mass-market commodities.
Italy is one of Europe's most mature pet markets. The Assalco-Zoomark Report 2025 estimates over 65 million pets in Italian households, with more than 20 million between dogs and cats — cats are approximately 12 million, growing by 1 million year-on-year. The pet food market for dogs and cats exceeded EUR 3.1 billion in 2024 with +13.4%, the second consecutive double-digit year, and a 2021-2024 CAGR of +9.8% in value. Mars Group generated over EUR 600 million in Italy across Mars Italia, Royal Canin Italia and AniCura Italia Holding. Nestlé is the leader in pet food promotional flyers with roughly 20% share, Mars at 11%, Affinity at 8.2% in the first nine months of 2024. Average spend per pet is around EUR 900 per year; pet insurance subscriptions grew 40% in the 2020-2025 period according to IntermediaChannel.
Livestock: AMR pressure changes the business model
The livestock segment — production animals: cattle, pigs, poultry, sheep and goats, aquaculture — operates within a structurally different framework. The decision-maker is not the emotionally involved owner, it is the farmer or the supply-chain integrator with efficiency KPIs per kilo produced, feed cost and margin per head. Italy has 23 companies belonging to AISA Federchimica, the sector association for animal health, covering approximately EUR 650 million in revenue and 95% of the Italian veterinary medicines market. The AISA president for 2024-2027 is Paolo Sani of MSD Animal Health. Italian supply-chain stakeholders include ASSALZOO for feed, UNAITALIA for poultry, Confagricoltura, AIA for farmers, and FNOVI and ANMVI for veterinarians.
The structural driver that has reshaped livestock pharma over the last five years is AMR pressure — Antimicrobial Resistance. EU Regulation 2019/6 on veterinary medicines, in force since January 2022, has banned routine use of antibiotics for prophylactic purposes, has restricted metaphylaxis and set the target of a 50% reduction in sales of antimicrobials for farming and aquaculture by 2030 versus 2018. The EMA ESVAC report published in 2024 documents a cumulative 53% reduction in antimicrobial use in EU food-producing animals between 2010 and 2022. The regulatory constraint is not theoretical: it has shifted livestock pharma value away from antibiotic volumes and toward vaccines, diagnostics, biosecurity and functional nutrition, with significant consequences on vendor portfolio mix.
Two decision-makers, two CRMs
The structural duality of the animal health market requires separate commercial and CRM architectures. In the pet care segment the primary decision-maker is the clinic veterinarian, with frequent touchpoints — the vet sees the pet at least two-three times per year for visits and prophylaxis — and a rapid decision cycle. The pet owner is an important influencer and in some cases secondary prescriber, especially on food, supplements and over-the-counter parasiticides. The primary sales channel is the veterinarian themselves or the veterinary pharmacy; D2C grows in specific segments such as premium food. The commercial message is centered on animal wellbeing and the humanization of the relationship.
In the livestock segment the primary decision-maker is the farm veterinarian or the nutritionist consultant, with a longer decision cycle, highly structured cost-benefit assessments, and very strict antibiotic traceability documentation requirements due to Reg. EU 2019/6. The farmer is co-decision-maker on many choices but prescription remains with the veterinarian, with mandatory electronic prescriptions tracking every administration. The commercial message is centered on efficiency per kilo produced, AMR compliance and biosecurity. Companies that have built a unified CRM for the two worlds — same application, same flows, same segmentation — accumulate significant technical debt: the two catalogues do not speak semantically, the two commercial processes do not share KPIs, the forecast models are not comparable. Companies that have separated — Zoetis, Boehringer Ingelheim Animal Health, Elanco — operate with distinct structures that coordinate at the governance level but do not share operations.
The message for Italy 2026
The Italian veterinary market is in an interesting phase of transformation. The pet care segment is one of Europe's most mature, with high average spend levels per pet, growing pet insurance penetration (market at USD 685.7 million in 2024 with CAGR of 15.6% to 2033 according to Grand View), consolidation of veterinary clinics into chains (AniCura, IVC Evidensia, independent Italian groups such as AVELIA founded in 2024). The livestock segment is fragmented by supply chain — dairy, pork, poultry, sheep-and-goats — and by geography, with concentration in Lombardy, Emilia and Veneto in the north and a different structure in the south. A unified "Italy animal health" CRM platform does not work: a modular architecture is needed that recognizes the duality.
For a veterinary pharma company planning investments in Italy in 2026 the agenda is clear. The first decision is on portfolio segmentation between pet and livestock, and the alignment of the commercial organization accordingly. The second is the choice of CRM and content infrastructure, which must enable coexistence of the two worlds without forcing them onto the same process. The third is compliance with EU Regulation 2019/6 on antimicrobial traceability, which is a product and data flow constraint, not just a commercial message constraint. The three decisions are independent, but if managed well they reinforce each other. If managed poorly, they generate the inefficiency that structured competitors exploit.
